SCHEMBL279970

SCHEMBL279970

Cc1ccc(C(=O)CN2CCNCC2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.43
HTR1A P08908 1/20 0.42
ALDH1A1 P00352 5/20 0.40
POLB P06746 3/20 0.40
HPGD P15428 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM3 P20309 1/20 0.40
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
ACHE P22303 1/20 0.39
MAPT P10636 1/20 0.38
DUSP3 P51452 1/20 0.38
PTPN5 P54829 1/20 0.38
PTPN11 Q06124 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280132 0.85 SMN1; SMN2 (0.46) DAOHTR1AALDH1A1POLBHPGD
SCHEMBL279616 0.84 RAB9A (0.49) DAOHTR1AALDH1A1HPGDRAB9A
SCHEMBL279637 0.83 ALDH1A1 (0.49) DAOHTR1AALDH1A1POLBHPGD
SCHEMBL279862 0.82 ALDH1A1 (0.51) DAOALDH1A1POLBHPGDRAB9A
SCHEMBL279617 0.81 DAO (0.42) DAOHTR1AALDH1A1POLBHPGD
SCHEMBL279992 0.77 DAO (0.44) DAOHTR1AALDH1A1POLBHPGD
SCHEMBL16284226 0.76 HPGD (0.57) DAOHTR1AALDH1A1POLBHPGD
SCHEMBL15219321 0.76 L3MBTL1 (0.51) ALDH1A1POLBRAB9ANPC1KMT2A
SCHEMBL279886 0.74 ALDH1A1 (0.42) DAOHTR1AALDH1A1POLBHPGD
SCHEMBL2616165 0.73 MEN1 (0.69) ALDH1A1CHRM5CHRM3RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL DAO 1673/4885HTR1A 1005/4885ALDH1A1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.